The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP ...

Biosimilar denosumab offers significant cost savings and improved access to treatment, alleviating financial burdens in ...

In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of Accessible Medicines tackle the FDA's recent draft guidance on comparative ...

In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of ...

Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar ...

Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...

After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

November 2025 highlights FDA approvals for denosumab and pertuzumab biosimilars, enhancing competition and access in oncology and bone health markets.

The IQVIA Institute for Human Data Science’s most recent Global Use of Medicines report projected that market introductions of new biosimilar and generic drugs will increase projected losses for ...